Vorinostat Completed Phase 2 Trials for Acute Myeloid Leukemia With 11q23-abnormality in Relapse Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01550224Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)